30 closest matches · ranked by relevance
HIV Infections
Primary: Proportion of Sexual Exposures Covered by Pre- and Post-exposure Dosing — 75; 56; 52; 85 percentage of sexual exposures
HIV Prevention · HIV Infections
Primary: Retention, Measured as the Number of HIV Exposure Events That Were Retained in Care at the 24 Week Follow-up Visit — 125; 157 HIV Exposure Events — p=<0.05
HIV/AIDS · PrEP
Primary: Engagement in Care (Implementation Component) — 1; 1 Participants
HIV-1 Infections · HIV Infections
Primary: Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants — 0.65; 0.50; 1.99 events per 100 person years — p=<0.001
HIV/AIDS
Primary: Number of Participants Achieving Appropriate Levels of Tenofovir-diphosphate (TFV-DP) at 6-month Follow-up — 78; 39 Participants
Pre-exposure Prophylaxis
Primary: Difference in Tenofovir-diphosphate (TFV-DP) Levels Between Intervention and Control Arms at 6 Months Follow-up — 17; 7 Participants
HIV Prevention
Primary: Number of Participants With a Grade 2 or Higher Adverse Event by Cohort — 230; 0 Participants
HIV Infection
Primary: Occurrence of Grade 3 or Higher Adverse Events (AEs) — 18; 24; 20; 28 Participants
HIV Infections
Primary: Estimated Threshold of Maternal Steady-state Tenofovir Diphosphate (TFV-DP) Concentration Levels Corresponding to Optimal Adherence in the PK Component — 965; 1050…
HIV
Primary: Number of Participants With PrEP Initiation — 192; 120; 426 Participants — p=<.0001
HIV Infections
Primary: Medication Regimen Completion Rates — 57; 28; 15 participants
HIV Infections
Primary: Measurement of Acceptance Rate of PrEP — 921; 557 Participants
HIV Prevention
Primary: Adherence to PrEP — 22; 11; 30; 54 Participants
HIV-1-infection
Primary: Recent PrEP Adherence — 33; 18 Participants — p=<0.001
HIV/AIDS · Adherence
Primary: Enacted Adherence as Measured by Electronic Monitoring at 6 and 24 Months — 40.2; 36.8; 27.0; 26.6 percentage of adherence
HIV Infection
Primary: Number of Participants With Serum Creatinine Event of Grade 1 or Higher Over the Course of the Study — 0 Participants
HIV Infections
Primary: The Percentage of Participants Who Report Willingness to Use the Study Regimen, Take up PrEP, and Remain on PrEP as Part of a Comprehensive Prevention Package — 148…
HIV Prevention
Primary: PrEP Uptake — 16.2; 11.4 days
Hiv · Substance Use Disorders
Primary: Intracellular Level of Tenofovir Diphosphate Levels Via Dried Blood Spot at 6-month Follow-up — NA fmol/punch
Human Immunodeficiency Virus
Primary: Number of Participants Continuing PrEP — 2 Participants
Human Immunodeficiency Virus
Primary: Evidence of Toxicity. Toxicity Was Measured as Any Adverse Event; Nausea, Vomiting, Diarrhea. Elevated Liver Function Tests. — 4; 4 adverse events
Human Immunodeficiency Virus
Primary: PrEP Adherence Via Biological Measures (Binary) — 47; 34; 11; 19 Participants
HIV Infection
Primary: Number of Participants With Serum Creatinine Event of Grade 1 or Higher — 1 Participants
HIV
Primary: Efficacy as Assessed by the Number of Participants Who Were HIV Positive at 6 Months — 0 participants
Human Immunodeficiency Virus
Primary: Number of Adverse Event Occurrences — 38; 28; 28; 14 events
HIV
Primary: Actual Number of Study Visits Completed by 24 Weeks — 3.5927; 4.6263; 4.6374 Visits — p=0.6983
Human Immunodeficiency Virus (HIV)
Primary: Number of Participants With Early Discontinuation From Randomized Human Immunodeficiency Virus Postexposure Prophylaxis (HIV PEP) — 10; 15 participants — p=0.2434
COVID-19 · Corona Virus Infection · ARDS
Primary: COVID-19-free Survival — 464; 468; 454 Participants
Sexually Transmitted Diseases
Primary: Rectal Doxycycline Concentration — 0.654 µg/g
HIV/AIDS · Adherence, Medication · Drug Use
Primary: Baseline TFV (Tenofovir) Levels in Plasma